Clinical Research Directory
Browse clinical research sites, groups, and studies.
68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
Sponsor: Peking Union Medical College Hospital
Summary
Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. Lung cancer tissues express fibroblast activating protein FAP, and also have high expression of integrin αVβ3 receptor on the surface of blood vessels. In this study, a novel dual-target imaging agent 68Ga-FAPI-RGD was used for PET/CT imaging of lung cancer.
Official title: A Pilot Study of 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2022-09-03
Completion Date
2025-12-31
Last Updated
2024-07-05
Healthy Volunteers
No
Conditions
Interventions
68Ga-FAPI-RGD
Intravenous injection of 68Ga-FAPI-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
18F-FDG
Intravenous injection of 18F-FDG with a dosage of approximately 3.7-5.55 MBq (0.1-0.15 mCi)/kg.
68Ga-FAPI
Intravenous injection of 68Ga-FAPI with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
68Ga-RGD
Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
Locations (1)
Peking Union Medical College Hospital
Beijing, China